Key facts
- It has raised $3.4M; the latest was Later Stage VC ($150K) in Mar 2026.
- Notable investors include First Fund, The University of British Columbia.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Andira Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Andira Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Andira Pharmaceuticals
Operator of a biopharmaceutical company intended to commercialise breakthrough advancements for infection control and other unmet needs healthcare indications. The company offers cannabinoid therapeutics treatments and consumer healthcare products using their research information, which can be used to treat infectious and oncological diseases, enabling patients to receive effective treatments with the help of natural medicines.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2020
- Website
- andira.ca/
- Ownership
- Privately Held (backing)
Andira Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Andira Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Andira Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.